Board changes and COO appointment at Okairos
This article was originally published in Scrip
T-cell vaccine specialist Okairos has appointed Bill Burns and Jean-Paul Prieels to its board of directors, and Tom Woiwode COO. Mr Burns, previously CEO of Roche's pharmaceutical division, will take the role of chairman. He and Mr Prieels, former head of research at GSK Vaccines, are replacing Thomas Szucs and Francesco Sinigaglia, who are both retiring. Mr Woiwode most recently served as COO of Euro Ventures.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.